Quant Biomarkers AG

Quant Biomarkers aims to revolutionize renal and cardiometabolic health with novel early biomarker test and AI-driven solution. Based in Switzerland, we address chronic kidney disease (CKD), impacting 700 million people globally and costing $155 billion annually.
We focus on early CKD risk detection and prognosis.
Our goal is to enable pre-emptive actions before the onset and during the early stages of CKD.
By developing novel biomarkers and leveraging AI, we create tools to assess risk and guide clinical decisions, leading to the preservation of kidney tissue and function, as well as reduced disease burden and costs.
Our solution RenoRisk ®, is an integrated risk prognostic test and software solution that combines patented novel biomarkers and machine learning model (ML).